Press release
Focal Segmental Glomerulosclerosis Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight
"Focal Segmental Glomerulosclerosis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Focal Segmental Glomerulosclerosis Market.
The Focal Segmental Glomerulosclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Focal Segmental Glomerulosclerosis Pipeline Report: https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Focal Segmental Glomerulosclerosis treatment therapies with a considerable amount of success over the years.
• Focal Segmental Glomerulosclerosis companies working in the treatment market are Dimerix Bioscience, Travere Therapeutics, Walden Biosciences, ZyVersa Therapeutics, Sanofi, and others, are developing therapies for the Focal Segmental Glomerulosclerosis treatment
• Emerging Focal Segmental Glomerulosclerosis therapies in the different phases of clinical trials are- DMX-200, Sparsentan, WAL0921, VAR 200-01, Brivekimig, and others are expected to have a significant impact on the Focal Segmental Glomerulosclerosis market in the coming years.
• In June 2025, The DUPLEX trial (NCT03493685) found that the dual endothelin-angiotensin receptor antagonist sparsentan led to a sustained decrease in proteinuria in patients with focal segmental glomerulosclerosis (FSGS).
• In May 2025, Travere Therapeutics, Inc. revealed that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking traditional approval for FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS).
• In April 2025, Dimerix Limited and Amicus Therapeutics announced they have signed an exclusive licensing agreement for the U.S. commercialization of Dimerix's Phase III drug candidate DMX-200 for all indications, including FSGS. Dimerix will retain all rights to commercialize DMX-200 in territories outside those covered by the exclusive U.S. license
• In January 2025, Dimerix entered into an exclusive development and licensing agreement with Fuso Pharmaceutical Industries Pty Ltd in Japan for the development and commercialization of its ACTION3 Phase III drug candidate, DMX-200, aimed at treating focal segmental glomerulosclerosis (FSGS) kidney disease.
Focal Segmental Glomerulosclerosis Overview
The hallmark of focal and segmental obliteration of glomerular capillary tufts inside enlarged matrix is known as focal segmental glomerular sclerosis (FSGS). FSGS is categorized based on the location and nature of the sclerotic lesion into collapsing, tip, cellular, perihilar, and not otherwise defined forms.
Get a Free Sample PDF Report to know more about Focal Segmental Glomerulosclerosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Focal Segmental Glomerulosclerosis Drugs Under Different Phases of Clinical Development Include:
• Research programme Oligonucleotides: Ceptur Therapeutics
• EG-102: Evergreen Therapeutics
• D4-101-02: Delta4
• OCX-063: Certa Therapeutics
• BI764198: Boehringer Ingelheim
• R3R 01: River 3 Renal Corp
• DMX-200: Dimerix Bioscience
• Sparsentan: Travere Therapeutics, Inc.
Focal Segmental Glomerulosclerosis Route of Administration
Focal Segmental Glomerulosclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Intramuscular
Focal Segmental Glomerulosclerosis Molecule Type
Focal Segmental Glomerulosclerosis Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
Focal Segmental Glomerulosclerosis Pipeline Therapeutics Assessment
• Focal Segmental Glomerulosclerosis Assessment by Product Type
• Focal Segmental Glomerulosclerosis By Stage and Product Type
• Focal Segmental Glomerulosclerosis Assessment by Route of Administration
• Focal Segmental Glomerulosclerosis By Stage and Route of Administration
• Focal Segmental Glomerulosclerosis Assessment by Molecule Type
• Focal Segmental Glomerulosclerosis by Stage and Molecule Type
DelveInsight's Focal Segmental Glomerulosclerosis Report covers around 18+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Focal Segmental Glomerulosclerosis product details are provided in the report. Download the Focal Segmental Glomerulosclerosis pipeline report to learn more about the emerging Focal Segmental Glomerulosclerosis therapies
https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Focal Segmental Glomerulosclerosis Therapeutics Market include:
Key companies developing therapies for Focal Segmental Glomerulosclerosis are - B. Braun Melsungen AG, Beckman Coulter Inc. (Danaher), Baxter International Inc., ChemoCentryx Inc., Complexa Inc., Dimerix Ltd, Medtronic PLC, Pfizer Inc., Retrophin Inc., Variant Pharmaceuticals Inc., and others.
Focal Segmental Glomerulosclerosis Pipeline Analysis:
The Focal Segmental Glomerulosclerosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Focal Segmental Glomerulosclerosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Focal Segmental Glomerulosclerosis Treatment.
• Focal Segmental Glomerulosclerosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Focal Segmental Glomerulosclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Focal Segmental Glomerulosclerosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Focal Segmental Glomerulosclerosis drugs and therapies
https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Focal Segmental Glomerulosclerosis Pipeline Market Drivers
• Surge of interest in developing new therapies for FSGS, renaissance in clinical research in nephrology are some of the important factors that are fueling the Focal Segmental Glomerulosclerosis Market.
Focal Segmental Glomerulosclerosis Pipeline Market Barriers
• However, the etiology and pathogenesis of Focal Segmental Glomerulosclerosis are very complex, high cost associated with the disease and other factors are creating obstacles in the Focal Segmental Glomerulosclerosis Market growth.
Scope of Focal Segmental Glomerulosclerosis Pipeline Drug Insight
• Coverage: Global
• Key Focal Segmental Glomerulosclerosis Companies: Dimerix Bioscience, Travere Therapeutics, Walden Biosciences, ZyVersa Therapeutics, Sanofi, and others
• Key Focal Segmental Glomerulosclerosis Therapies: DMX-200, Sparsentan, WAL0921, VAR 200-01, Brivekimig, and others
• Focal Segmental Glomerulosclerosis Therapeutic Assessment: Focal Segmental Glomerulosclerosis current marketed and Focal Segmental Glomerulosclerosis emerging therapies
• Focal Segmental Glomerulosclerosis Market Dynamics: Focal Segmental Glomerulosclerosis market drivers and Focal Segmental Glomerulosclerosis market barriers
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Focal Segmental Glomerulosclerosis Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight here
News-ID: 4170707 • Views: …
More Releases from DelveInsight Business Research
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Pois …
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Summary
NF1-PN Market Set to Grow Beyond USD 380 Million by 2034 driven by rising diagnosed cases, better awareness, advanced diagnostics, and genetic testing. In the US alone, ~97,000 diagnosed NF1 cases were reported in 2023, expected to increase by 2034. Treatment remains challenging-surgery is often complex, risky, and prone to recurrence, leaving significant unmet needs, especially in pediatric patients with inoperable PNs. Current…
DelveInsight Unveils Competitive Landscape Assessment: Unlocking Opportunities i …
DelveInsight, a leading business consulting and market intelligence firm in healthcare, announces the release of its latest Competitive Landscape Assessment Case Study, showcasing opportunities in the dissolvable microneedle technology (dMTS) space. This in-depth analysis highlights how strategic evaluations and tailored solutions can enable global healthcare organizations to expand product offerings, secure intellectual property, and strengthen their competitive positions in the rapidly growing drug delivery market.
Gain firsthand access to a complimentary…
Competitive Intelligence in the Hematology Domain: Driving Strategic Success thr …
DelveInsight, a leader in healthcare consulting and competitive intelligence, has recently showcased its success in a long-term engagement for competitive intelligence support within the hematology domain. This case study highlights how timely, in-depth competitive intelligence empowered a Europe-based client to refine strategies, strengthen launch preparedness, and maintain a leadership position in the face of intense competition.
The rapidly evolving field of hematological malignancies, including Acute Myeloid Leukemia (AML), Multiple Myeloma, and…
Hepatic Encephalopathy Market Expected to Gain Momentum Through 2034, According …
DelveInsight's "Hepatic Encephalopathy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Hepatic Encephalopathy, historical and forecasted epidemiology as well as the Hepatic Encephalopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Hepatic Encephalopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hepatic Encephalopathy Market Forecast
https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Focal
Focal Epilepsy Market New Product Development & Latest Trends
Introduction
Focal epilepsy, the most common form of epilepsy worldwide, originates in specific regions of the brain and often presents with partial seizures. Affecting millions of people globally, focal epilepsy remains a pressing neurological challenge with significant clinical and economic impact. Increasing diagnosis rates, technological advances in imaging and neurostimulation, and new pharmacological approaches are fueling rapid changes in the treatment landscape.
As healthcare systems place greater emphasis on effective long-term management…
Focal Segmental Glomerulosclerosis Market Size Report 2024
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Focal Segmental Glomerulosclerosis Drugs Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $22.41 billion In…
3D FOCAL LINES SPATULA TECHNOLOGY for SYGMALIFT
Focal Ultrasounds in three-dimensional (3D) technology expand to the Face Lifting and V Facing. This innovation is able to treat volume that contains every conceivable plane (X, Y, Z angles) within the region of interest such as Double Chin or Cheeks.
While there is no doubt that there are advantages to volume treatment in 2.5 Seconds only, it delivers more power and add clinical benefit to target submental and jawlines…
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics - Pipeline Analysis 2018
Focal segmental glomerulosclerosis (FSGS) is a glomerular disease, which is characterized by scarring or sclerosis in the kidney. Scarring damages the limited number of glomeruli in the initial stages. It is more common in males than in females, anad is very common in African American population.
Download the sample report @ https://www.pharmaproff.com/request-sample/1090
FSGS can be caused by many diseases like diabetes, sickle cell disease, and HIV infection. It is categorized into two…
Focal Segmental Glomerulosclerosis (FSGS) Market Report 2018: Segmentation by Di …
Global Focal Segmental Glomerulosclerosis (FSGS) market research report provides company profile for Variant Pharmaceuticals, Inc., GlaxoSmithKline plc., Novartis AG, ChemoCentryx, Inc., Retrophin, Inc., AbbVie, Inc., AstraZeneca plc., Pfizer, Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd. and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth…
Africa Energy Week – Three Different Focal Points, One Conference
Africa’s development in oil and gas has significantly increased over the last few years; Ghana’s Jubilee field, first discovered in 2007, is now producing 70,000 barrels a day and may climb to 120,000 by the end of the year. With much of its oil for export, the country’s economic growth is climbing at a rapid rate, and many are looking to follow suit. Local content has since been a hot…
